PET Tau - Neurodegenerative Disease Imaging

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

August 23, 2016

Primary Completion Date

September 30, 2030

Study Completion Date

September 30, 2030

Conditions
Neurodegenerative Disease
Interventions
DRUG

18F-AV-1451

"The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain.~Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit.~The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania."

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Avid Radiopharmaceuticals

INDUSTRY

lead

University of Pennsylvania

OTHER